Transbiohope | TRANSBIO clinical study enrolment of patients advances as planned
Transbio project, oriented to the development of an in vitro diagnostic kit for the treatment of chronic rejection with immunosuppressants. H2020 program of the European Union
"trasplante riñón” “diagnóstico in vitro” “in vitro diagnosis” “trasplante renal” “H2020” “European Commission project” “renal transplant” “kidney transplant” “start-up” “Tres Cantos” “biomedicina” “biomedicine” “biotechnology” “immunobiogram” “inmunobiograma” “tratamiento inmunosupresores” “Treatment with immunosuppressants”
16288
post-template-default,single,single-post,postid-16288,single-format-standard,ajax_fade,page_not_loaded,,qode-theme-ver-10.1.1,wpb-js-composer js-comp-ver-5.0.1,vc_responsive
 

TRANSBIO clinical study enrolment of patients advances as planned

TRANSBIO clinical study enrolment of patients advances as planned

The TRANSBIO clinical study started the inclusion of patients on June 2018 and since then 139 patients have been enrolled. Most of the participating hospitals, from 5 different countries, are already actively recruiting in the planned rate. Therefore, we expect to recruit the total of 200 patients in February 2019 and have preliminary results by Q12019.

The 9 centres involved in the TRANSBIO clinical study are the University Hospital, Hospital del Mar and Hospital Vall’d Hebron (Barcelona, Spain); the Hospital Puerta de Hierro, Hospital La Paz and Hospital 12 de octubre (Madrid, Spain); the RigsHospitalet (Copenhague, Denmark); the Universitätsklinikum Essen (Germany); the University Hospital Borowska (Wroclaw, Poland) and the Massachusetts General Hospital (Boston, USA).

The Transbio clinical study results will confirm the potential clinical utility observed in the preliminary clinical study BH-PILOT, that shown promising results of IMMUNOBIOGRAM® as an in vitro test to adjust immunosuppressive therapy in a personalized way in patients with kidney transplantation in 70 patients’ samples.The Transbio clinical study results will confirm the potential clinical utility observed in the preliminary clinical study BH-PILOT, that shown promising results of IMMUNOBIOGRAM® as an in vitro test to adjust immunosuppressive therapy in a personalized way in 70 patients with kidney transplantation.